Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2690402, 10 pages
https://doi.org/10.1155/2017/2690402
Research Article

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis

1Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
2Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, EPE, Lisbon Academic Medical Centre, Lisboa, Portugal
3EpiDoC Unit, CEDOC, NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal
4Musculoskeletal Diseases and Inflammation Research Group, Biomedicum Helsinki 1, Faculty of Medicine, Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland

Correspondence should be addressed to Inês P. Perpétuo; moc.liamg@outeprep.seni

Received 1 October 2016; Accepted 4 January 2017; Published 13 February 2017

Academic Editor: Sadiq Umar

Copyright © 2017 Inês P. Perpétuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Schett, S. Hayer, J. Zwerina, K. Redlich, and J. S. Smolen, “Mechanisms of disease: the link between RANKL and arthritic bone disease,” Nature Clinical Practice Rheumatology, vol. 1, no. 1, pp. 47–54, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Schett, “Review: immune cells and mediators of inflammatory arthritis,” Autoimmunity, vol. 41, no. 3, pp. 224–229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Cascão, R. A. Moura, I. Perpétuo et al., “Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis,” Arthritis Research & Therapy, vol. 12, no. 5, article R196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Appel, C. Loddenkemper, and P. Miossec, “Rheumatoid arthritis and ankylosing spondylitis—pathology of acute inflammation,” Clinical and Experimental Rheumatology, vol. 27, no. 4, supplement 55, pp. S15–S19, 2009. View at Google Scholar · View at Scopus
  6. G. P. Eng, P. Bouchelouche, E. M. Bartels et al., “Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive Cohort Study,” PLoS ONE, vol. 11, no. 9, Article ID e0162316, 2016. View at Publisher · View at Google Scholar
  7. M. Takeshita, K. Suzuki, J. Kikuchi et al., “Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis,” Cytokine, vol. 75, no. 2, pp. 222–227, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Zivojinovic, N. N. Pejnovic, M. N. Sefik-Bukilica, L. V. Kovacevic, I. I. Soldatovic, and N. S. Damjanov, “Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis,” Journal of Rheumatology, vol. 39, no. 1, pp. 18–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Hoff, T. K. Kvien, J. Kälvesten, A. Elden, A. Kavanaugh, and G. Haugeberg, “Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study,” BMC Musculoskeletal Disorders, vol. 12, article 54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Aletaha, T. Neogi, A. J. Silman et al., “2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569–2581, 2010. View at Google Scholar
  11. M. C. Hochberg, R. W. Chang, I. Dwosh, S. Lindsey, T. Pincus, and F. Wolfe, “The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 35, no. 5, pp. 498–502, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. I. P. Perpétuo, R. Raposeiro, J. Caetano-Lopes et al., “Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in ankylosing spondylitis,” PLoS ONE, vol. 10, no. 12, Article ID e0144655, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. Wong, W. H. Yeap, J. J. Y. Tai, S. M. Ong, T. M. Dang, and S. C. Wong, “The three human monocyte subsets: implications for health and disease,” Immunologic Research, vol. 53, no. 1–3, pp. 41–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Furneri, L. G. Mantovani, A. Belisari et al., “Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 30, no. 4, supplement 73, pp. S72–S84, 2012. View at Google Scholar · View at Scopus
  15. M. Husheem, J. K. E. Nyman, J. Vääräniemi, H. K. Vaananen, and T. A. Hentunen, “Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay,” Calcified Tissue International, vol. 76, no. 3, pp. 222–230, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. L. K. Osier, S. N. Popoff, and S. C. Marks Jr., “Osteopetrosis in the toothless rat: failure of osteoclast differentiation and function,” Bone and Mineral, vol. 3, no. 1, pp. 35–45, 1987. View at Google Scholar
  17. N. Kurihara, T. Suda, Y. Miura et al., “Generation of osteoclasts from isolated hematopoietic progenitor cells,” Blood, vol. 74, no. 4, pp. 1295–1302, 1989. View at Google Scholar · View at Scopus
  18. T. R. Arnett and D. W. Dempster, “A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins,” Endocrinology, vol. 120, no. 2, pp. 602–608, 1987. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Ye, G. Coulouris, I. Zaretskaya, I. Cutcutache, S. Rozen, and T. L. Madden, “Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction,” BMC Bioinformatics, vol. 13, article 134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Wong and J. F. Medrano, “Real-time PCR for mRNA quantitation,” BioTechniques, vol. 39, no. 1, pp. 75–85, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Caetano-Lopes, A. Rodrigues, A. Lopes et al., “Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression,” Clinical Reviews in Allergy and Immunology, vol. 47, no. 1, pp. 38–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Fransen and P. L. C. M. van Riel, “The Disease Activity Score and the EULAR response criteria,” Clinical and Experimental Rheumatology, vol. 23, no. 5, supplement 39, pp. S93–S99, 2005. View at Google Scholar · View at Scopus
  23. D. van der Heijde, G. Burmester, J. Melo-Gomes et al., “Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1113–1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Blache, T. Lequerré, A. Roucheux et al., “Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept,” Rheumatology, vol. 50, no. 10, Article ID ker183, pp. 1814–1822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. I. Catrina, E. Af Klint, S. Ernestam et al., “Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 76–81, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. L. R. Coulthard, J. Geiler, R. J. Mathews et al., “Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients,” Clinical & Experimental Immunology, vol. 170, no. 1, pp. 36–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Toubi, A. Kessel, Z. Mahmudov, K. Hallas, M. Rozenbaum, and I. Rosner, “Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab,” Annals of the New York Academy of Sciences, vol. 1051, pp. 506–514, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. I. Catrina, C. Trollmo, E. Af Klint et al., “Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report,” Arthritis and Rheumatism, vol. 52, no. 1, pp. 61–72, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Wijbrandts, P. H. Remans, P. L. Klarenbeek et al., “Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3330–3339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Huang, B. Yang, Y. Shi et al., “Anti-TNF-α therapy improves treg and suppresses teff in patients with rheumatoid arthritis,” Cellular Immunology, vol. 279, no. 1, pp. 25–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. L. W. Moreland, R. P. Bucy, M. E. Weinblatt, K. M. Mohler, G. T. Spencer-Green, and W. W. Chatham, “Immune function in patients with rheumatoid arthritis treated with etanercept,” Clinical Immunology, vol. 103, no. 1, pp. 13–21, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. T. J. M. Smeets, M. C. Kraan, M. E. van Loon, and P.-P. Tak, “Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue,” Arthritis & Rheumatism, vol. 48, no. 8, pp. 2155–2162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Aeberli, R. Kamgang, D. Balani, W. Hofstetter, P. M. Villiger, and M. Seitz, “Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis,” RMD Open, vol. 2, no. 1, Article ID e000079, 2016. View at Publisher · View at Google Scholar
  34. S. Sprangers, T. Schoenmaker, Y. Cao, V. Everts, and T. J. de Vries, “Different blood-borne human osteoclast precursors respond in distinct ways to IL-17A,” Journal of Cellular Physiology, vol. 231, no. 6, pp. 1249–1260, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Lim, S. R. Kwon, K. Joo, M. J. Son, S.-G. Park, and W. Park, “Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use,” Korean Journal of Internal Medicine, vol. 29, no. 6, pp. 807–813, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Gengenbacher, H.-J. Sebald, P. M. Villiger, W. Hofstetter, and M. Seitz, “Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 67, no. 5, pp. 620–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. I. González-Alvaro, A. M. Ortiz, E. G. Tomero et al., “Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists,” Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1675–1678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Ziolkowska, M. Kurowska, A. Radzikowska et al., “High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment,” Arthritis and Rheumatism, vol. 46, no. 7, pp. 1744–1753, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-G. Miao, Y.-Y. Yang, X. He et al., “Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling,” Cellular Signalling, vol. 25, no. 10, pp. 2069–2078, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-Y. Wang, Y.-Y. Liu, H. Ye et al., “Circulating dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis,” Journal of Rheumatology, vol. 38, no. 5, pp. 821–827, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Seriolo, S. Paolino, A. Sulli, and M. Cutolo, “Are there any positive effects of TNF-α blockers on bone metabolism?” Reumatismo, vol. 58, no. 3, pp. 199–205, 2006. View at Google Scholar · View at Scopus
  42. F. Chopin, P. Garnero, A. Le Henanff et al., “Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 353–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Yasunori, T. Masaaki, N. Tetsuyuki, K. Hayato, and N. Akira, “Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 27, no. 9, pp. 1093–1101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Costa-Rodrigues, A. Fernandes, and M. H. Fernandes, “Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14+ and CD14 cell fractions,” Cell Proliferation, vol. 44, no. 5, pp. 410–419, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Piper, A. Boyde, and S. J. Jones, “The relationship between the number of nuclei of an osteoclast and its resorptive capability in vitro,” Anatomy and Embryology, vol. 186, no. 4, pp. 291–299, 1992. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Matsuno, K. Yoshida, A. Ochiai, and M. Okamoto, “Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 12, pp. 2326–2333, 2007. View at Google Scholar · View at Scopus
  47. L. M. Childs, J. J. Goater, R. J. O'Keefe, and E. M. Schwarz, “Efficacy of etanercept for wear debris-induced osteolysis,” Journal of Bone and Mineral Research, vol. 16, no. 2, pp. 338–347, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Y. A. Terry, M. I. Koenders, G. M. Franssen et al., “Monitoring therapy response of experimental arthritis with radiolabeled tracers targeting fibroblasts, macrophages, or integrin αvβ3,” Journal of Nuclear Medicine, vol. 57, no. 3, pp. 467–472, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Yago, Y. Nanke, N. Ichikawa et al., “IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: a novel mechanism of osteoclastogenesis by IL-17,” Journal of Cellular Biochemistry, vol. 108, no. 4, pp. 947–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C.-K. Lee, E. Y. Lee, S. M. Chung, S. H. Mun, B. Yoo, and H.-B. Moon, “Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand,” Arthritis & Rheumatism, vol. 50, no. 12, pp. 3831–3843, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. N. B. Binder, A. Puchner, B. Niederreiter et al., “Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 65, no. 3, pp. 608–617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. T. J. de Vries, J. Yousovich, T. Schoenmaker, N. Scheres, and V. Everts, “Tumor necrosis factor-α antagonist infliximab inhibits osteoclast formation of peripheral blood mononuclear cells but does not affect periodontal ligament fibroblast-mediated osteoclast formation,” Journal of Periodontal Research, vol. 51, no. 2, pp. 186–195, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Yago, Y. Nanke, M. Kawamoto et al., “IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats,” Arthritis Research and Therapy, vol. 9, no. 5, article R96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Takita, Y. Fujikawa, I. Itonaga, H. Taira, M. Kawashima, and T. Torisu, “Infliximab acts directly on human osteoclast precursors and enhances osteoclast formation induced by receptor activator of nuclear factor κB ligand in vitro,” Modern Rheumatology, vol. 15, no. 2, pp. 97–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Kobayashi, N. Takahashi, E. Jimi et al., “Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction,” Journal of Experimental Medicine, vol. 191, no. 2, pp. 275–286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Osta, G. Benedetti, and P. Miossec, “Classical and paradoxical effects of TNF-α on bone homeostasis,” Frontiers in Immunology, vol. 5, article 48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. S. L. Teitelbaum and F. P. Ross, “Genetic regulation of osteoclast development and function,” Nature Reviews Genetics, vol. 4, no. 8, pp. 638–649, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Bozec, L. Bakiri, A. Hoebertz et al., “Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia,” Nature, vol. 454, no. 7201, pp. 221–225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Ainola, H. Valleala, P. Nykänen, J. Risteli, R. Hanemaaijer, and Y. T. Konttinen, “Erosive arthritis in a patient with pycnodysostosis: an experiment of nature,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3394–3401, 2008. View at Publisher · View at Google Scholar · View at Scopus